Nuvation Bio Competitors

Nuvation Bio (NYSE:NUVB) and AbCellera Biologics (NASDAQ:ABCL) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership and earnings.

Valuation and Earnings

This table compares Nuvation Bio and AbCellera Biologics' gross revenue, earnings per share and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Nuvation Bio and AbCellera Biologics, as provided by MarketBeat.com.

Nuvation Bio currently has a consensus target price of $17.40, indicating a potential upside of 74.00%. AbCellera Biologics has a consensus target price of $52.80, indicating a potential upside of 89.11%. Given AbCellera Biologics' higher possible upside, analysts clearly believe AbCellera Biologics is more favorable than Nuvation Bio.

Profitability

This table compares Nuvation Bio and AbCellera Biologics' net margins, return on equity and return on assets.

Nuvation Bio (NYSE:NUVB) and Sana Biotechnology (NASDAQ:SANA) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership and earnings.

Valuation and Earnings

This table compares Nuvation Bio and Sana Biotechnology's gross revenue, earnings per share and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Nuvation Bio and Sana Biotechnology, as provided by MarketBeat.com.

Nuvation Bio currently has a consensus target price of $17.40, indicating a potential upside of 74.00%. Sana Biotechnology has a consensus target price of $40.00, indicating a potential upside of 51.46%. Given Nuvation Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Nuvation Bio is more favorable than Sana Biotechnology.

Profitability

This table compares Nuvation Bio and Sana Biotechnology's net margins, return on equity and return on assets.

Summary

Nuvation Bio beats Sana Biotechnology on 3 of the 3 factors compared between the two stocks.

Nuvation Bio (NYSE:NUVB) and Abcam (NASDAQ:ABCM) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership and earnings.

Profitability

This table compares Nuvation Bio and Abcam's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Nuvation Bio and Abcam, as provided by MarketBeat.com.

Nuvation Bio currently has a consensus target price of $17.40, indicating a potential upside of 74.00%. Abcam has a consensus target price of $22.00, indicating a potential upside of 13.23%. Given Nuvation Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Nuvation Bio is more favorable than Abcam.

Valuation and Earnings

This table compares Nuvation Bio and Abcam's gross revenue, earnings per share and valuation.

Summary

Nuvation Bio beats Abcam on 3 of the 3 factors compared between the two stocks.

Seer (NASDAQ:SEER) and Nuvation Bio (NYSE:NUVB) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Seer and Nuvation Bio, as provided by MarketBeat.com.

Seer currently has a consensus target price of $68.00, indicating a potential upside of 26.98%. Nuvation Bio has a consensus target price of $17.40, indicating a potential upside of 74.00%. Given Nuvation Bio's stronger consensus rating and higher probable upside, analysts plainly believe Nuvation Bio is more favorable than Seer.

Profitability

This table compares Seer and Nuvation Bio's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Seer and Nuvation Bio's revenue, earnings per share and valuation.

Summary

Nuvation Bio beats Seer on 3 of the 3 factors compared between the two stocks.

Nuvation Bio (NYSE:NUVB) and ImmunityBio (NASDAQ:IBRX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk.

Analyst Ratings

This is a summary of current ratings for Nuvation Bio and ImmunityBio, as provided by MarketBeat.com.

Nuvation Bio currently has a consensus price target of $17.40, indicating a potential upside of 74.00%. ImmunityBio has a consensus price target of $25.00, indicating a potential upside of 55.38%. Given Nuvation Bio's higher probable upside, equities research analysts plainly believe Nuvation Bio is more favorable than ImmunityBio.

Profitability

This table compares Nuvation Bio and ImmunityBio's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Nuvation Bio and ImmunityBio's revenue, earnings per share (EPS) and valuation.

Summary

Nuvation Bio beats ImmunityBio on 2 of the 2 factors compared between the two stocks.

Nuvation Bio (NYSE:NUVB) and BioAtla (NASDAQ:BCAB) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk.

Analyst Ratings

This is a summary of current ratings for Nuvation Bio and BioAtla, as provided by MarketBeat.com.

Nuvation Bio currently has a consensus price target of $17.40, indicating a potential upside of 74.00%. BioAtla has a consensus price target of $58.00, indicating a potential upside of 20.26%. Given Nuvation Bio's higher probable upside, equities research analysts plainly believe Nuvation Bio is more favorable than BioAtla.

Profitability

This table compares Nuvation Bio and BioAtla's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Nuvation Bio and BioAtla's revenue, earnings per share (EPS) and valuation.

Summary

Nuvation Bio beats BioAtla on 2 of the 2 factors compared between the two stocks.